ASH 2018 | CD19 CAR T-cells plus ibrutinib in R/R CLL may improve response & decrease CRS
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
Jordan Gauthier, MD, of the Fred Hutchinson Cancer Research Center, Seattle, WA, presents the results of the comparison of the efficacy and toxicity of CD19-directed CAR T-cells alone or in combination with ibrutinib for relapsed/refractory chronic lymphocytic leukemia (CLL). He highlights the conclusions that ibrutinib treatment rfom 2 weeks before leukapheresis until 3 months after JCAR014 was well tolerated in the majority of patients, and may decrease the incidence of severe cytokine release synfrome and improve response rates. This video was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Get great new content delivered to your inboxSign up